Lupin launches liraglutide injection in US market

Global pharma major Lupin Limited today announced the launch of Liraglutide Injection, 18 mg/3 mL (6 mg/mL) single-patient-use prefilled pen, in the United States. This product is bioequivalent to Victoza® Injection and is indicated for improving glycemic control in adults and pediatric patients aged 10 years and older with type 2 diabetes mellitus.

According to IQVIA MAT Aug 2025 data, the RLD Victoza® had an estimated annual sale of $350 million in the U.S. This launch marks a significant milestone for Lupin, enhancing its complex injectables portfolio and increasing access to essential therapies for patients.

Spiro Gavaris, president – U.S. generics, Lupin, emphasized that this move underscores the company's commitment to making critical medications more accessible. Lupin distributes products across over 100 markets and maintains a strong presence in therapy areas including anti-diabetic care.